CTNMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Contineum Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Jul 30, 2026
$7.44+0.36 (+5.08%)
Close on Oct 19, 2026
- Market cap
- $278.76M
- P/E (TTM)
- –
- Dividend yield
- –
Contineum Therapeutics statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Pharmaceutical Preparations companies for comparison
Valuation
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Market Cap | $279.90M | $166.30M |
| Enterprise Value | $43.30M | $88.19M |
| PB Ratio | 1.17 | 2.03 |
| P/TBV Ratio | 1.17 | 2.29 |
Income (trailing twelve months)
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Operating Income | -$66.38M | -$21.40M |
| Net Income | -$57.56M | -$22.46M |
| EBITDA | -$66.00M | -$16.91M |
| EPS (Diluted) | -$1.73 | -$0.83 |
Returns
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Return on Equity (ROE) | -28.0% | -53.2% |
| Return on Assets (ROA) | -26.6% | -40.9% |
| Return on Capital Employed (ROCE) | -27.2% | -38.1% |
Balance sheet
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $236.60M | $61.43M |
| Net Cash (Debt) | $236.60M | $15.35M |
| Net Cash Per Share | $6.29 | $0.66 |
| Equity (Book Value) | $239.66M | $49.09M |
| Book Value Per Share | $6.37 | $1.37 |
| Tangible Book Value | $239.66M | $23.52M |
| Working Capital | $236.05M | $76.81M |
Financial position
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Current Ratio | 37.17 | 3.34 |
| Quick Ratio | 36.26 | 2.44 |
Cash flow (trailing twelve months)
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Operating Cash Flow | -$53.01M | -$12.35M |
| Capital Expenditures | -$458.00K | -$1.08M |
| Free Cash Flow | -$53.46M | -$20.22M |
| FCF Per Share | -$1.42 | -$0.42 |
Efficiency
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Profits Per Employee | -$1.13M | -$703.34K |
| Employee Count | 51 | 74 |
Dividends and yields
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Earnings Yield | -20.6% | -23.3% |
| FCF Yield | -19.1% | -8.72% |
Shares
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Shares Outstanding | 37,621,100 | 58,127,000 |
| Shares Change (YoY) | 29.5% | 10.9% |
| Float | 37,434,300 | 49,136,700 |
| Shares Held by Insiders | 0.50% | 11.6% |
| Shares Held by Institutions | 81.2% | 59.4% |
Scores
| Measure | Contineum Therapeutics | Industry median |
|---|---|---|
| Altman Z-Score | 14.78 | -0.22 |
| Piotroski F-Score | 4 | 4 |
Calculated by StockData from Contineum Therapeutics's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.